Body: I-SPY 2, a multicenter phase 2 neoadjuvant trial in high-risk breast cancer, uses adaptive randomization within biomarker subtypes to evaluate novel agents added to standard chemotherapy. In addition to efficiently evaluating agent/signature pairs, I-SPY 2 is a biomarker rich trial, where samples are profiled for gene expression, protein levels, and mutation status. Biomarkers are classified as established, qualifying, or exploratory. Established biomarkers are those used clinically (HR/HER2 status) or FDA cleared (MammaPrint), and used for adaptive randomization to generate the 10 signatures from which a drug can graduate. Qualifying biomarkers (QB) represent evidence-based, biologic pathway markers (e.g.cell line predictors, known drug targets). QB analyses must be pre-specified and performed under CLIA. Exploratory markers are for discovery and may allow integration of data from different technologies.
Julia D Wulfkuhle, Christina Yau, Denise M Wolf, Isela Gallagher, Ashish Sanil, Lamorna Brown-Swigart, Susan Flynn, Gillian Hirst, I-SPY 2 TRIAL Investigators, Meredith Buxton, Angela DeMichele, Nola Hylton, Fraser Symmans, Laura van 't Veer, Doug Yee, Melissa Paoloni, Laura Esserman, Don Berry, Minetta Liu, John W Park, Emanuel F Petricoin Evaluation of HER family protein signaling network as a predictive biomarker for pCR for breast cancer patients treated with neratinib in the I-SPY 2 TRIAL Background: We hypothesize that response to the pan-ERBB inhibitor, neratinib (N), may be predicted by pre-treatment HER2-EGFR signaling. In the I-SPY 2 TRIAL, N graduated in the HR-/HER2+ signature. All patients received at least standard chemotherapy. For HER2+ patients, N was administered in place of trastuzumab. We evaluated 18 HER family signaling proteins as biomarkers of N response using reverse phase protein microarray (RPMA) data from pre-treatment LCM purified tumor epithelium.
Methods: 168 patients (N: 106, concurrent controls: 62) had RPMA and pCR data. 18 biomarkers relating to HER family signaling were evaluated: AKT S473, AKT T308, EGFR, EGFR Y1068, EGFR Y1148, EGFR Y1173, EGFR Y992, ERBB2, ERBB2 Y1248, ERBB3 total, ERBB3 Y1289, ERK1/2 T202/Y204, Heregulin, mTOR, mTOR S2448, PI3K p85 Y458/p55 Y199, PTEN S380, and SHC Y317. We assessed association between biomarker and response in the N and control arms alone (likelihood ratio test), and relative performance between arms (biomarker x treatment interaction) using a logistic model. Analysis was also performed adjusting for HR/HER2 status. In an exploratory analysis, we selected the marker with the greatest interaction (phosphorylated EGFR (Y1173)) to dichotomize patients optimally based on the data and assessed it in the context of the graduating signature by adding the EGFR Y1173-High patients to the HR-/HER2+ subtype and evaluating the treatment effect in this 'biomarker-positive' group. Our study is exploratory with no claims for generalizability of the data and does not account for multiplicities. Statistical calculations are descriptive (e.g. p-values are measures of distance with no inferential content).
Results: 7 HER pathway markers (EGFR Y1068, EGFR Y1173, EGFR Y992, ERBB2 total, ERBB2 Y1248, ERBB3 Y1289, SHC Y317) are associated with response in the N but not the control arm. However, the difference in performance between arms did not reach significance by permutation testing. Adjusting for HR/HER2 status, EGFR Y1173 shows a significant biomarker x treatment interaction (p = 0.049). In an exploratory analysis, we dichotomized patients by their EGFR Y1173 levels and evaluated the distribution of pCR rates (Table 1) . Neratinib (n=106) Control ( classification was added to HR and HER2 to define the cancer subtypes used in the I SPY 2 adaptive randomization engine. Neratinib (N), one of the experimental agents evaluated in I SPY 2, graduated in the HR HER2+ signature. All patients received at least standard chemotherapy (paclitaxel followed by doxorubicin/cyclophosphamide; T >AC). HER2 patients were randomized to receive N+T >AC vs. T >AC. For HER2+ patients, neratinib was administered in place of trastuzumab (N+T >AC vs. H+T >AC). Here, we assess the performance of MP1/MP2 class as a specific biomarker of neratinib response.
Methods: 115 patients in the neratinib arm and 76 concurrently randomized controls had Agilent 44K microarrays and pCR data available for analysis. We assess association between MP1/MP2 and response in the neratinib and control arms alone using Fisher's exact test, and relative performance between arms (biomarker x treatment interaction, likelihood ratio p < 0.05) using a logistic model. This analysis is also performed adjusting for HR status as a covariate, and in receptor subsets. Our study is exploratory with no claims for generalizability of the data. Statistical calculations are descriptive (e.g. p values are measures of distance with no inferential content). Our analyses do not adjust for multiplicities of other biomarkers in the trial but outside this study.
Results: There are 133 MP1 patients (neratinib: 74, Control: 59) and 58 MP2 patients (neratinib: 41, Control: 17), 84% (49) of which are Her2 . The distribution of pCR rates among MP1/MP2 dichotomized groups are summarized in Table 1. MP2, one of the 10 eligible signatures, did not meet the graduation threshold; and MP1/MP2 did not show a significant biomarker x treatment interaction (OR in neratinib relative to control arm = 1.25). The MP1/MP2 x treatment interaction remains non significant after adjustment for HR and HER2 status (p=0.54). In HER2 patients receiving neratinib, 45% (15/33) of MP2 patients achieved a pCR, compared to 0% (0/17) of MP1 patients. In the HER2 controls, there is a 31% pCR rate in MP2 (5/16) vs. 18% in MP1 (7/39) patients (OR=2.14). This difference in performance between treatment arms appears significant (p=0.041). 90% of HER2+ patients are MP1, thus MP1/MP2 status x treatment interaction within the HER2+ subtype cannot be evaluated.
Conclusion: Within the I SPY 2 population as a whole, MP1/MP2 stratification does not appear to be a specific biomarker of response to neratinib relative to the control arm. The number of HER2 patients is small and precludes any definitive conclusion, but these data motivate further investigation of the biological mechanisms distinguishing MP1 from MP2 to better understand chemotherapy and/or neratanib responsiveness. classification was added to HR and Her2 to define the cancer subtypes used in the I-SPY 2 adaptive randomization engine. HER2-patients were randomized to receive standard chemotherapy or the oral PARP inhibitor veliparib in combination with carboplatin (V/C) and chemotherapy. V/C graduated in the triple-negative (TN) signature, where MP2 was not an eligible signature for graduation. Here, we assess the performance of MP1/MP2 class as a specific biomarker of response to V/C.
Methods: 115 HER2-patients (V/C: 71 and concurrent controls: 44) were considered in this analysis. We assess association between MP1/MP2 and response in the V/C and control arms alone using Fisher's exact test, and relative performance between arms (biomarker x treatment interaction, likelihood ratio p < 0.05) using a logistic model. This analysis is also performed adjusting for HR status as a covariate. To assess MP1/MP2 in the context of the graduating signature, we added the MP2 patients to the graduating TN subset and evaluated the treatment effect in this 'biomarker-positive' group. Our study is exploratory with no claims for generalizability of the data. Statistical calculations are descriptive (e.g. pvalues are measures of distance with no inferential content). This analysis does not adjust for multiplicities of other biomarkers in the trial but outside this study.
Results:
In the V/C arm vs. concurrent controls, there were 66 MP1 (V/C: 32, Control: 34) and 49 MP2 patients (V/C: 39, Control: 10), 78% of which are TN. The distribution of pCR rates among MP1/MP2 dichotomized groups are summarized in Table 1 .
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The OR between MP1/MP2 risk groups for predicting pCR is 9.71 in the V/C arm (p=6.63E-05), in comparison to an OR of 0.97 in the control arm (p=1). There is a significant biomarker x treatment interaction (p=0.023), which remains upon adjusting for HR status (p= 0.028). Based on the I-SPY 2 Bayesian model, a Phase III trial with 300 MP2 patients has a 95% predictive probability of success.
When the MP2 patients are added to the graduating TN subset, the OR associated with V/C is 4.36, which is comparable to that of the TN signature (OR: 4.29), while increasing the prevalence of biomarker-positive patients by 10%.
Conclusion:
In our exploratory analysis, MP2 suggests higher sensitivity to V/C combination therapy relative to controls. This observation has prompted an investigation into the biological mechanisms distinguishing the MP1/MP2 subtype that may account for this specificity. Body: Background: We developed a 7-gene DNA-repair deficiency signature (PARPi-7) that predicts breast cancer cell line sensitivity to the PARP inhibitor olaparib [PMID: 22875744] . We hypothesized that this signature would also predict response to other PARP inhibitors including veliparib. In the I-SPY 2 TRIAL, HER2-patients were randomized to receive standard chemotherapy or the oral PARP inhibitor veliparib in combination with carboplatin (V/C) and chemotherapy. V/C graduated in the triple-negative (TN) signature. Here we assess the PARPi-7 as a specific biomarker of V/C response.
Title: Evaluation of an in vitro derived
Methods: 115 HER2-patients (V/C: 71 and concurrent controls: 44) were considered in this analysis. The PARPi-7 signature score is computed from Agilent 44K array data as published using expression levels of BRCA1, CHEK2, MAPKAPK2, MRE11A, NBN, TDG, and XPA. We assess association between PARPi-7 and response in the V/C and control arms alone (Wald p < 0.05), and relative performance between arms (biomarker x treatment interaction, likelihood ratio p < 0.05) using a logistic model. In an exploratory analysis, we dichotomized patients by the PARPi-7 score using the published in vitro derived cutpoint (0.037). To assess PARPi-7 in the context of the graduating signature, we added the PARPi-7 High patients to the graduating TN subset and evaluated the treatment effect in this 'biomarker-positive' group. Our study is exploratory with no claims for generalizability of the data. Statistical calculations are descriptive (e.g. p-values are measures of distance with no inferential content). Our analyses do not adjust for multiplicities of other biomarkers in the trial but outside this study. Results: The PARPi-7 signature associates with patient response in the V/C arm (OR = 3.9, p=0.00056) but not in the control arm (OR = 0.87, p=0.68). There is a significant biomarker x treatment interaction (OR in V/C arm relative to control arm = 4.48, p=0.0028), which remains significant upon adjusting for HR status (p=0.0018). In an exploratory analysis, PARPi-7 dichotomized using the published in vitro derived cutpoint yields 62 PARPi-7 Low and 53 PARPi-7 High patients. 26% of PARPi-7 High patients are not TN. The distribution of pCR rates among PARPi-7 dichotomized groups are in Table 1 .
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When the PARPi-7 High patients are added to the graduating TN subset, the OR associated with V/C is 5.12, which is comparable to that of the TN signature (OR: 4.29), while increasing the prevalence of biomarker-positive patients by 12%. Evaluation of PARPi-7 in the context of the graduating signature under the I-SPY 2 Bayesian model is pending. Conclusion: Our sample size is small. Our pre-specified analysis suggests the PARPi-7 signature shows promise for predicting response to veliparib/carboplatin combination therapy relative to control. If verified in a larger trial, this cell-line derived signature may contribute to the selection criteria of PARP inhibitor trials in the future. Title: Detrimental effects of sequential compared to concurrent treatment of Pertuzumab plus T-DM1 in HER2+ breast cancer cell lines Body: Background. Pertuzumab and T-DM1 are two recently approved monoclonal antibody based therapies targeting HER2+ breast cancer. Pertuzumab interferes with dimerization of HER family members, while T-DM1 binds to HER2 and interferes with its oncogenic function while also specifically delivering a cytotoxic agent (emtansine). One arm of the I-SPY 2 clinical trial is to investigate the efficacy of a combination Pertuzumab plus T-DM1 in HER2+ breast cancer patients. Methods. We performed preclinical screening of response to each agent alone and in combination in a set of 21 HER2+ breast cancer cell lines, with an end goal of identifying markers of response to the therapies. There were five treatment regimens employed in the initial screen: i) pertuzumab alone for 72 h; ii) T-DM1 alone for 72h; iii) pertuzumab plus T-DM1 concurrently for 72h; iv) pertuzumab for 24h followed by addition of T-DM1 for 48h more; and iv) T-DM1 for 24h followed by addition of pertuzumab for 48h more. Response was assessed using the Cell Titer Glo assay as a measure of cell viability. To assess the effects of drug combinations, we used a stringent measure of synergy and antagonism employing the median effect method of Chou and Talalay that included 95% confidence intervals to determine significance. Results. Initial screens showed that concurrent treatment of cells with pertuzumab plus T-DM1 gave significant synergistic interactions in 15/21 cell lines as measured by the median effect method, with combination indices (CI) less than 0.5 (and 95% upper confidence levels less than 1.0) for at least one drug concentration. However, 24h pretreatment with pertuzumab followed by T-DM1 significantly diminished the response of cells to T-DM1, resulting in significant antagonism in 17/21 cell lines test (CI>1.5, lower confidence level greater than 1). Since this could be due to a shorter exposure time to T-DM1, and since patients are scheduled to be treated with pertuzumab first followed by T-DM1 one hour later, we repeated the experiment with one hour between pertuzumab and T-DM1 rather than 24h. While the inhibitory effect was diminished, this treatment regimen still resulted in significant antagonism when T-DM1 was given 1 hour after pertuzumab in 5/5 cell lines tested, in contrast to concurrent pertuzumab plus T-DM1 treatment, which showed synergy. Conclusions. Pertuzumab plus T-DM1 appears to be beneficial when given concurrently, but pretreatment with pertuzumab appears to blunt the efficacy of T-DM1. This has important potential ramifications for patient treatment, and may further elucidate mechanisms of action for both compounds. Further testing will be necessary to determine whether these timing effects are operational in vivo and whether immune effects mitigate the antagonism. 
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